Loxo, Bayer’s Vitrakvi wins FDA approval. Now comes the hard part: finding patients

Loxo, Bayer’s Vitrakvi wins FDA approval. Now comes the hard part: finding patients

An oncologist compared NTRK fusion patients to a needle in a haystack, but had some clues of how to find them. Still, drugs like Vitrakvi call for genomic sequencing of all cancer patients, he said.

Source: https://ift.tt/2KBLTOa